← board
CELUW
distress 5/10 · elevated risk$0.01+691%today0% from 52w high
Revenue
$27M
Liquidity
$9M
Runway
0.7 yrs
Shares 1y
+8%
Price & events
+3.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+690.9%
1D
+0.0%
1W
+0.0%
1M
+0.0%
3M
—
6M
—
1Y
—
2Y
—
5Y
+3.0%
All
Overview
- Market Cap
- $251.83K
- Volume
- 0
- 52 Week Range
- $0.00 – $0.01
- Total Shares
- 28.95M
- Float Shares
- 18.87M
- Beta
- 0.54
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2025-08-13partnershipAsset purchase and license agreement with Celeniv to sell IP for $33.8M, retire debt, license back with repurchase optionSEC 8-K
- 2025-08-05partnershipEntered into Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. for $2,890,250 of product purchase credits.SEC 8-K
- 2025-02-24partnershipMaster Services Collaboration Agreement with BlueSphere Bio for manufacturing of TCR T cell therapies targeting AMLSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.